SOAT1 and ovarian cancer: Previous reports have used combined inhibition of activated STAT signaling pathways and IL-6 as a therapeutic approach against drug-resistant cells, and other studies have shown that Taxol resistance in ovarian cancer can be overcome by inhibiting IL-6 and STAT3 [33, 34].